U.S. markets closed

Apyx Medical Corporation (APYX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.50+0.35 (+3.83%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close9.15
Bid8.90 x 800
Ask9.47 x 800
Day's Range9.17 - 9.57
52 Week Range2.81 - 12.01
Avg. Volume97,937
Market Cap326.02M
Beta (5Y Monthly)0.74
PE Ratio (TTM)N/A
EPS (TTM)-0.35
Earnings DateMay 10, 2021 - May 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Apyx Medical Posts Lower-Than-Expected 4Q Loss, Beats On Revenues

    Apyx Medical Posts Lower-Than-Expected 4Q Loss, Beats On Revenues

    Apyx Medical Corp. reported a smaller-than-feared loss in the fourth quarter. Moreover, revenues topped analysts’ expectations. Shares of the advanced energy technology company rose 2.2% to close at $9.88 on March 30. Apyx Medical (APYX) incurred a loss of $0.04 per share in 4Q, compared to the $0.11 loss per share estimated by analysts. A loss of $0.16 per share was reported in the same quarter last year. Total revenues generated in the quarter increased 36.8% to $11.5 million and came in well ahead of the consensus estimate of $9.62 million. The company’s Advanced Energy segment sales jumped 44% year-over-year, while sales for the OEM segment grew 4%. Additionally, gross margin increased 80 basis points to 67.2%. (See Apyx Medical stock analysis on TipRanks) Apyx Medical CEO Charlie Goodwin said, “We introduced full year 2021 financial guidance which calls for revenue growth in the range of 32% to 40% year-over-year, driven by Advanced Energy growth of 45% to 55% year-over-year. Importantly, our guidance assumes that strong handpiece demand from global customers will be the largest contributor to our year-over-year growth, coupled with measured improvement in the capital equipment environment as we move through the year.” For 2021, the company projects total revenues to land between $36.7 million and $38.7 million, versus the consensus estimate of $39.15 million. Net loss is forecasted to be in the range of $20.7 million to $18.4 million. On March 30, Colliers Securities analyst Kyle Bauser maintained a Buy rating and a price target of $14 (41.7% upside potential). Apyx Medical shares have exploded 175.2% over the past year, while the stock still scores a Strong Buy consensus rating, based on 4 unanimous Buys. That’s alongside an average analyst price target of $12.50, which implies 26.5% upside potential to current levels. On top of this, Apyx Medical scores a 9 out of 10 from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations. Related News: Millendo To Merge With Tempest Therapeutics; Shares Tank Fly Leasing To Be Acquired By Carlyle Aviation Partners For $2.36B; Shares Pop 28% McCormick’s 1Q Results Beat Expectations As Sales Outperform More recent articles from Smarter Analyst: FactSet’s FY21 EPS Guidance Disappoints After 2Q Miss Wall Street Roundup: Bullish & Bearish Calls Of The Day Hyatt Plans Major Footprint Expansion In India Vipshop To Buy Back $500M In Stock; Shares Pop 9%

  • Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates

    Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates

    Apyx (APYX) delivered earnings and revenue surprises of 69.23% and 3.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Apyx Medical Corporation Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Outlook

    Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its fourth quarter and full year ended December 31, 2020, and introduced financial expectations for the full year ending December 31, 2021.